Description

This edition of the Drug Discovery TOE depicts trends across rare and genetic diseases. In addition to key facts and findings, life sciences and pharmaceutical industry trends that are driving rare and genetic diseases interventions, as well as, the global macro trends demanding therapeutic solutions for rare and genetic diseases are illustrated.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Rare diseases, genetic diseases, inborn errors, metabolism errors, pediatric diseases, gene therapy, plasma biologics, automatic DNA sequencing, next generation sequencing, genetic diagnostic services, genetic diagnostics, orphan product development, lysosomal storage disease, multiple rare and genetic disorders